Featured Lymphoma Content
Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.
Lymphoma News and Features
Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.
A weekly dose of temsirolimus 75 mg was found to be active in patients with relapsed/refractory primary CNS lymphoma (PCNSL); however, only some patients achieved long-term control.
A new approach in T cell immunotherapy uses a small protein tag to hasten and improve the immunotherapy's ability to attack cancer cells.
Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.
Higher body weight and increased height during adolescence increase the risk for developing certain subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.
[OncoTargets and Therapy] Anaplastic large cell lymphoma (ALCL) frequently involves the bone marrow, but primary or secondary involvement to the bone is rare. This article examines a case of anaplastic lymphoma kinase positive ALCL with prominent bone involvement in a young boy.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
- Breast Cancer Tumors Often a Composite of Tumor Types, Enhancing Treatment Resistance
- Physical Activity May Reduce Mortality by 44% in Patients With Breast Cancer
- Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed
- PMPS: A Common Late Effect of Surgery and Radiation for Breast Cancer
- Early Tumor Size Change May Predict OS in Metastatic Breast Cancer
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer
- Nurses Are Key to Referrals to Inpatient Integrative Medicine Services
- Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma
- Poor Compliance to Adjuvant Chemo Linked to Poorer Survival in Rectal Cancer
- Users Support Indoor Tanning Device Age Restrictions, Stronger Health Warnings, But Not Total Ban
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|